GU Cancers 2025 | Phase I trial of SHR-A2102, a nectin-4 targeted ADC, in urothelial carcinoma
Jun Guo
• 14 Feb 2025
(NCT05735275) of SHR-A2102, a nectin-4 targeted antibody-drug conjugate (ADC), in patients with advanced or metastatic urothelial carcinoma. SHR-A2102 demonstrated encouraging anti-tumor activity, including in those previously treated with antibody-drug conjugates. Higher dose levels were associated with improved responses. The treatment had a manageable safety profile, with common adverse events including anemia and decreased white blood cell counts. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
